The Assumption Everyone Makes
Ask any pharma executive to rank formulation preferences and you will get the same answer: oral first, subcutaneous second, intravenous last. The logic is intuitive. Patients prefer pills to needles. Payers prefer drugs that do not require clinic administration costs. Physicians prefer therapies that do not consume infusion chair time. The oral formulation wins on every axis.
Except it does not. Not always. And the reasons it fails are structural, economic, and deeply embedded in how American healthcare actually reimburses physician-administered drugs.
I have watched this assumption survive contact with reality in multiple launch scenarios, and the pattern is consistent enough to deserve its own analysis. The conventional wisdom about oral superiority is not wrong in theory — it is incomplete in practice. And that incompleteness has cost multiple launch teams months of lost time when they discovered, too late, that the prescriber economics were working against them.
How Buy-and-Bill Actually Works
To understand why oral does not always win, you need to understand Medicare Part B reimbursement for physician-administered drugs — the mechanism known as buy-and-bill.
When a community oncologist administers an infused or injected drug in their clinic, the reimbursement pathway works like this: the practice purchases the drug at the wholesale acquisition cost (WAC) or a negotiated group purchasing organization (GPO) price. Medicare reimburses the practice at the Average Sales Price (ASP) plus 6%. That 6% margin — plus any delta between the practice’s acquisition cost and ASP — represents direct revenue to the practice (CMS, Medicare Part B Drug Payment Policy, 42 CFR 414.904).
This is not a trivial number. For a drug with an annual cost of $150,000, the ASP+6% margin alone represents approximately $9,000 per patient per year in practice revenue. Multiply that across a panel of 20-30 patients on the same drug, and you are looking at $180,000-$270,000 in annual practice revenue from a single product’s buy-and-bill margin — before accounting for administration fees, which Medicare reimburses separately under HCPCS J-codes.
Community oncology practices — which treat approximately 80% of all cancer patients in the United States (Community Oncology Alliance, Practice Impact Report, 2023) — depend on this revenue. It is not a bonus. For many practices, infusion revenue is a structural component of the business model, subsidizing the overhead of maintaining treatment chairs, nursing staff, pharmacy operations, and the administrative infrastructure that keeps a community cancer center operational.
What Happens When Oral Replaces Infusion
When an oral formulation enters a therapeutic area previously served by an infused or injectable drug, the reimbursement channel shifts from Part B (medical benefit) to Part D (pharmacy benefit). This is not a technical nuance — it is a fundamental restructuring of who gets paid and how.
Under Part B, the prescribing practice purchases, administers, and is reimbursed for the drug. The practice is an economic participant in the transaction.
Under Part D, the drug flows through a specialty pharmacy. The prescriber writes a prescription, but the practice has no economic involvement in the drug’s distribution, administration, or reimbursement. The buy-and-bill margin disappears. The administration fee disappears. The patient stops coming to the infusion center for that particular drug, potentially reducing visit frequency and the downstream ancillary revenue associated with those visits (lab draws, imaging, other services scheduled around infusion appointments).
For the individual community oncologist, switching a stable patient from a Part B infusion to a Part D oral means the practice loses revenue. Not in the abstract — in the quarterly P&L.
The MDS Case Study
This dynamic plays out with particular clarity in lower-risk myelodysplastic syndromes (MDS). Reblozyl (luspatercept), a first-in-class erythroid maturation agent, is a subcutaneous injection administered every 3 weeks in the clinic. It is reimbursed under Part B. BMS’s hematology franchise — built on years of Revlimid and Vidaza relationships — is deeply embedded in the community hematology infrastructure.
Now consider the launch scenario for an oral erythropoiesis modifier targeting the same SF3B1-mutant lower-risk MDS population. The clinical value proposition is straightforward: comparable efficacy (Phase 3 transfusion independence rate of approximately 42% versus Reblozyl’s 38% in MEDALIST) with oral convenience. On paper, this should be an easy win.
In practice, the economic forces push back. The community hematologist currently earns buy-and-bill margin on Reblozyl. The practice earns administration fees for each subcutaneous injection visit. The patient returns to the clinic every 3 weeks, maintaining a regular touchpoint that supports the broader care relationship.
An oral agent eliminates all three revenue streams. The practice does not buy the drug. It does not administer the drug. The patient may not need to return as frequently. The clinical benefit of convenience is real, but the economic cost to the practice is also real — and the decision-maker at the point of prescribing feels both.
This is not to suggest that community oncologists prescribe based on practice revenue rather than clinical merit. But in a scenario where two therapies offer comparable efficacy, and one generates practice revenue while the other does not, the economic alignment creates inertia that the oral formulation must overcome with a clear and unambiguous clinical advantage. “Comparable with convenience” is not enough.
The Patient Cost Problem
The irony deepens when you examine the patient’s out-of-pocket exposure.
Under Medicare Part B, the patient’s cost-sharing responsibility is 20% of the Medicare-approved amount after the Part B deductible. For a drug costing $150,000 annually, that is approximately $30,000 before Medigap or supplemental coverage — but the vast majority of Medicare beneficiaries carry supplemental insurance that covers most or all of the Part B coinsurance. The patient’s actual out-of-pocket for a Part B drug is often modest and predictable.
Under Medicare Part D, an oral specialty drug is typically placed on a specialty tier (Tier 5), where cost-sharing is structured as a percentage of the drug cost rather than a fixed copay. Before the Inflation Reduction Act’s $2,000 out-of-pocket cap (effective 2025), Medicare Part D specialty tier copays for oral oncology drugs averaged $7,000-$10,000 per year during the coverage gap phase (Kaiser Family Foundation, Medicare Part D Specialty Drug Cost Analysis, 2023). Even with the IRA cap, the Part D structure creates cost exposure that is less familiar, less predictable, and more anxiety-inducing for patients on fixed incomes than the Part B pathway they have been navigating.
For MDS patients — median age approximately 70, frequently managing multiple comorbidities, often on fixed retirement incomes — the shift from Part B to Part D can feel like a step backward in affordability, even when the drug itself is clinically equivalent or superior.
The oral agent that was supposed to make life easier for the patient may actually make it more financially complicated.
The Academic-Community Split
The economics play differently in academic medical centers versus community practices, and this split matters strategically.
Academic medical centers typically employ physicians on salary. The buy-and-bill margin accrues to the institution, not the individual prescriber. Academic physicians are less directly incentivized by the Part B revenue stream and more influenced by clinical evidence, guideline recommendations, and peer opinion. They are structurally more receptive to oral formulations on clinical merit.
Community oncologists, by contrast, are often practice owners or partners whose compensation is directly tied to practice revenue. The buy-and-bill economics are personal. And community practices treat the majority of patients — roughly 80% of all cancer care in the U.S. is delivered in the community setting (COA, 2023).
This creates a strategic dilemma for the oral formulation’s launch team: the prescribers most receptive to your product treat fewer patients, and the prescribers who treat the most patients have economic reasons to resist switching.
A field force strategy that leads with academic KOLs will build scientific credibility. But the revenue trajectory depends on community adoption, and community adoption faces economic headwinds that scientific data alone cannot overcome.
What the Oral Launch Team Actually Needs
Recognizing this dynamic does not mean oral formulations cannot win. It means the launch strategy must be designed for the economic reality, not the formulation preference assumption.
First, the copay program must be aggressive and seamless. For the oral MDS agent, the copay assistance program is not a patient services add-on — it is a market access requirement. If the patient’s out-of-pocket exposure is higher on the oral agent than on the injectable, the convenience narrative collapses. The hub must make Part D copays equal to or better than the patient’s Part B experience from day one.
Second, the value story must extend beyond formulation convenience. “Oral is easier” is a weak message when the prescriber loses revenue and the patient may pay more. The clinical differentiation must be real and measurable — not just directionally favorable in cross-trial comparison. Safety advantages, quality-of-life data, and patient-reported outcomes that go beyond convenience are essential.
Third, the field force must understand and address the economic conversation directly. Community oncologists know the economics. They will not raise it explicitly — but they will find clinical reasons to prefer the drug that also happens to generate practice revenue. The field team needs to be prepared for the unstated objection, not just the clinical one.
Fourth, the payer strategy must proactively address the channel economics. Working with payers to create coverage pathways that minimize the patient cost differential between Part B and Part D — or lobbying for site-of-care neutral reimbursement policies — is a longer-term play, but it addresses the structural root cause.
The Broader Lesson
The Part B buy-and-bill dynamic is a specific instance of a general principle: in pharmaceutical commercialization, the formulation preference of the patient is only one variable in a multi-stakeholder economic equation.
The prescriber has economic interests. The practice has operational interests. The payer has cost-management interests. The specialty pharmacy has distribution interests. When these interests align with the patient’s preference, adoption is frictionless. When they diverge, the product with the better clinical profile can still lose to the product with the better economic alignment.
This is not cynicism. It is the recognition that healthcare operates within economic systems, and launch strategies that ignore those systems in favor of clinical elegance will underperform.
The oral formulation may still win. But it will win because the launch team understood the economic headwinds and built a strategy to overcome them — not because they assumed convenience alone would carry the day.
Daniel Tran is a Hematology/Oncology Product Marketing Manager at Pfizer and a UCSD-trained PharmD specializing in launch strategy, competitive intelligence, and market access.